Top

News & Events

College Hill Life Sciences Secures a Clutch of New Mandates

College Hill Life Sciences Secures a Clutch of New Mandates

6 June 2013, London, Manchester, Munich, Boston, Sydney, Melbourne: The Life Sciences team of College Hill, part of the international business communications consultancy, College Group, continues to expand its portfolio with 11 additional client wins across both the private and public sectors in Europe, the USA and Australasia. New clients’ mandates span the Consultancy’s offering from fully retained services to branding and IR/PR projects.

In Europe, College Hill Life Sciences has been commissioned by Austrian-based UgiChem, and Stockholm-based SwedenBio. New UK clients include Autifony Therapeutics, Ockham Biotech, Atopix Therapeutics and, in the public sector, CPRD:

  • UgiChem, from Innsbruck in Austria, develops proprietary new gene silencing therapeutics, the so-called Ugimers, which overcome the shortcomings of established gene silencing technologies such as antisense oligonucleotides or siRNAs. The Company has signed up College Hill to support its media communications.
  • SwedenBIO will be holding the Nordic Life Science Days in Stockholm on 14-15 October 2013, in conjunction with Biopeople and the Finnish and Norwegian Bioindustry Associations. College Hill will support the development of key messages and the pre-event publicity, marketing, and media outreach, as well as running the press room during the two-day event.
  • Autifony Therapeutics is developing novel treatments for hearing disorders including hearing loss and tinnitus. College Hill is supporting media outreach on a project basis.
  • CPRD (Clinical Practice Research Datalink) is a secure, world-class, e-health research system that provides researchers world-wide with access to real-world patient data on a scale not previously possible. College Hill is working with the CPRD team to refine their messaging and to further develop targeted content for their marketing materials.
  • Atopix Therapeutics is a new biopharmaceutical company developing a novel class of anti-allergic medicines with assets acquired from Oxagen, for which College Hill has supported media relations.
  • Ockham Biotech focusses on the development of inhaled heparin for the treatment of obstructive airway diseases, including chronic obstructive pulmonary disease (COPD), cystic fibrosis and asthma. College Hill has supported media outreach around the announcement of the recovery of its EU patent.

In Australasia, the team has signed up two new clients from New Zealand, namely SeaDragon and Nexus6, as well as Cellmid in Australia.

  • SeaDragon is an NZX-listed producer of fish oils for health supplements. College Hill is working alongside local partner Merlin IR, supporting International out reach.
  • Nexus6 is a privately owned company offering eHealth solutions to improve patient adherence to respiratory medicine for example Asthma and COPD. College Hill will be leading on the execution of a global PR strategy.
  • Cellmid, an ASX-listed Sydney-based biotech company developing innovative new therapies and diagnostic tests for heart attack, inflammatory diseases and cancer signed up. College Hill to supporting International media communications around its financial transaction to acquire Advangen of Japan.

Finally in the USA, the team have successfully attracted two additional clients:

  • EndoStim is an American medical device company focused on treating Gastro-oesophageal Reflux Disease (GERD), commonly known as acid reflux, through electrical stimulation to ensure secure closing of the stomach valve. In collaboration with US partner PR firm Lazar Partners, the initial projects will focus on media campaigns in Germany for the roll out of its product which has recently received reimbursement at nine hospitals.
  • Kiyatec, a venture-backed company commercialising novel 3D cell culture technology, has sought input from College Hill to support its business plan development.

“It’s has been a bumper period for new business, which reflects a general up-tick in the life sciences sector globally, most notably in the USA. We are delighted to be supporting such a breadth of new clients in a variety of ways, with a focus as ever on delivering business communications in a way that enhances value creation”, said Sue Charles, Managing Partner at College Hill Life Sciences.

For further information:

Sue Charles
Managing Partner, Life Sciences
+44 (0)20 7457 2020
sue.charles@collegehill.com

back to news

People

Sue CharlesManaging Partner

Melanie Toyne-SewellManaging Partner

Tim WatsonPartner

Dr Eileen PaulAssociate Partner

Dr Christelle KerouedanAssociate Partner